82 related articles for article (PubMed ID: 2004369)
1. Decreasing sensitivity to cytotoxic agents parallels increasing tumorigenicity in human fibroblasts.
Kinsella AR; Haran MS
Cancer Res; 1991 Apr; 51(7):1855-9. PubMed ID: 2004369
[TBL] [Abstract][Full Text] [Related]
2. The propensity for gene amplification: a comparison of protocols, cell lines, and selection agents.
Sharma RC; Schimke RT
Mutat Res; 1994 Jan; 304(2):243-60. PubMed ID: 7506368
[TBL] [Abstract][Full Text] [Related]
3. Effect of tumor promoter 12-O-tetradecanoylphorbol-13-acetate on recovery of methotrexate-, N-(phosphonacetyl)-L-aspartate-, and cadmium-resistant colony-forming mouse and hamster cells.
Bojan F; Kinsella AR; Fox M
Cancer Res; 1983 Nov; 43(11):5217-21. PubMed ID: 6616458
[TBL] [Abstract][Full Text] [Related]
4. Influence of both salvage and DNA damage response pathways on resistance to chemotherapeutic antimetabolites.
Pickard M; Kinsella A
Biochem Pharmacol; 1996 Aug; 52(3):425-31. PubMed ID: 8687496
[TBL] [Abstract][Full Text] [Related]
5. p53 expression in normal versus transformed mammalian cells.
Moro F; Ottaggio L; Bonatti S; Simili M; Miele M; Bozzo S; Abbondandolo A
Carcinogenesis; 1995 Oct; 16(10):2435-40. PubMed ID: 7586148
[TBL] [Abstract][Full Text] [Related]
6. Drug resistance and gene amplification potential regulated by transforming growth factor beta 1 gene expression.
Huang A; Jin H; Wright JA
Cancer Res; 1995 Apr; 55(8):1758-62. PubMed ID: 7712485
[TBL] [Abstract][Full Text] [Related]
7. Generation of drug-resistant variants in metastatic B16 mouse melanoma cell lines.
Cillo C; Dick JE; Ling V; Hill RP
Cancer Res; 1987 May; 47(10):2604-8. PubMed ID: 3567893
[TBL] [Abstract][Full Text] [Related]
8. Increased methotrexate resistance and dhfr gene amplification as a consequence of induced Ha-ras expression in NIH 3T3 cells.
Wani MA; Xu X; Stambrook PJ
Cancer Res; 1994 May; 54(9):2504-8. PubMed ID: 8162600
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
[TBL] [Abstract][Full Text] [Related]
10. Multiple mechanisms of N-(phosphonoacetyl)-L-aspartate drug resistance in SV40-infected precrisis human fibroblasts.
Schaefer DI; Livanos EM; White AE; Tlsty TD
Cancer Res; 1993 Oct; 53(20):4946-51. PubMed ID: 8402685
[TBL] [Abstract][Full Text] [Related]
11. Suppression of gene amplification in human cell hybrids.
Tlsty TD; White A; Sanchez J
Science; 1992 Mar; 255(5050):1425-7. PubMed ID: 1542791
[TBL] [Abstract][Full Text] [Related]
12. Selection of N-(phosphonacetyl)-L-aspartate resistant Chinese hamster mutants in the presence of the uridine uptake inhibitor dipyridamole.
Tessera L; Mucciolo E; Bertoni L; Giulotto E
Anticancer Res; 1995; 15(1):189-92. PubMed ID: 7733632
[TBL] [Abstract][Full Text] [Related]
13. High frequency of double drug resistance in the B16 melanoma cell line.
McMillan TJ; Kalebic T; Stark GR; Hart IR
Eur J Cancer; 1990; 26(5):565-7. PubMed ID: 2144741
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor mediated alterations in drug resistance, and evidence of gene amplification.
Huang A; Wright JA
Oncogene; 1994 Feb; 9(2):491-9. PubMed ID: 7904743
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic resistance to methotrexate and N-phosphonacetyl L-aspartate is induced by treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA).
Kinsella AR; Fox M
Int J Cancer; 1988 Jul; 42(1):87-93. PubMed ID: 3391708
[TBL] [Abstract][Full Text] [Related]
16. Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).
Ardalan B; Jayaram HN; Johnson RK
Cancer Res; 1983 Apr; 43(4):1598-601. PubMed ID: 6831405
[TBL] [Abstract][Full Text] [Related]
17. Mechanism-based model for tumor drug resistance.
Kuczek T; Chan TC
Cancer Chemother Pharmacol; 1992; 30(5):355-9. PubMed ID: 1505073
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance in KHT fibrosarcoma cell lines with different metastatic ability.
Cillo C; Ling V; Hill RP
Int J Cancer; 1989 Jan; 43(1):107-11. PubMed ID: 2910823
[TBL] [Abstract][Full Text] [Related]
19. Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the de novo pyrimidine pathway.
Karle JM; Cowan KH; Chisena CA; Cysyk RL
Mol Pharmacol; 1986 Aug; 30(2):136-41. PubMed ID: 2874477
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
Chan TC; Howell SB
Cancer Res; 1985 Aug; 45(8):3598-604. PubMed ID: 4016741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
